Skip to content
Research Article Open access CC BY 4.0

Are Depot Anti-psychotics Associated with Longer Persistence in Treatment Compared with Oral Antipsychotics among Patients with Schizophrenia?

Increase Ibukun Adeosun

Journal of Pharmaceutical Research International · pp. 1–8 · Published 25 Aug 2017

10.9734/JPRI/2017/35581

Abstract

Aim: Non-adherence with antipsychotics is associated with poor outcomes in patients with schizophrenia. It was anticipated that drop-out from treatment due to non-compliance with oral anti-psychotics could be abated with the use of depot antipsychotics. However previous studies are divergent regarding the association between persistence in treatment and the use of depot antipsychotics. This study aimed to compare treatment persistence among out-patients with schizophrenia receiving depot versus oral antipsychotics in Lagos, Nigeria. Methodology: Relevant clinical data of out-patients with schizophrenia (n=160) were retrieved one year post-hospitalisation at a public psychiatric facility in Nigeria. Treatment persistence (time to all cause treatment discontinuation) among the cohort of patients was determined using the Kaplan-Meier Survival analyses. Persistence in treatment between patients receiving depot versus oral antipsychotic medications alone was compared using the log rank test. Results:  Nearly half (49.1%) of the cohort dropped out of treatment within one month of discharge, while 18.2% persisted for one year. There was no significant difference (p=0.727) in the mean duration of treatment persistence between patients receiving depot antipsychotics (17.4(±2.4) weeks), and those receiving oral medications alone (19.4 (±2.2) weeks). Conclusion: There is a high rate of drop-out from treatment among patients with schizophrenia, after discharge from in-patient care. Prescription of depot medications was not associated with longer persistence treatment in the studied cohort. This finding highlights the need to develop interventions to facilitate treatment persistence among patients with schizophrenia.

Schizophrenia anti-psychotics depot anti-psychotics treatment persistence medication adherence compliance drop-out.

References (33)

  1. 1 Prevalence, Severity, and Comorbidity of 12-Month DSM-IV Disorders in the National Comorbidity Survey Replication [DOI]
  2. 2 Determinants of Medication Compliance in Schizophrenia: Empirical and Clinical Findings [DOI]
  3. 3 Partial Compliance and Risk of Rehospitalization Among California Medicaid Patients With Schizophrenia [DOI]
  4. 4 Adherence to Treatment With Antipsychotic Medication and Health Care Costs Among Medicaid Beneficiaries With Schizophrenia [DOI]
  5. 5 Oral versus depot antipsychotic drugs for schizophrenia—A critical systematic review and meta-analysis of randomised long-term trials [DOI]
  6. 6 Long-Acting Injectable vs Oral Antipsychotics for Relapse Prevention in Schizophrenia: A Meta-Analysis of Randomized Trials [DOI]
  7. 7 Antipsychotic Medication Adherence: Is There a Difference Between Typical and Atypical Agents? [DOI]
  8. 8 Pharmacy Data Identify Poorly Adherent Patients With Schizophrenia at Increased Risk for Admission [DOI]
  9. 9 The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal [DOI]
  10. 10 Why don't patients attend their appointments? Maintaining engagement with psychiatric services [DOI]
  11. 11 Systematic meta-review of depot antipsychotic drugs for people with schizophrenia [DOI]
  12. 12 Using Drug Claims Data to Assess the Relationship of Medication Adherence With Hospitalization and Costs [DOI]
  13. 13 Antipsychotic Adherence Over Time Among Patients Receiving Treatment for Schizophrenia [DOI]
  14. 14 Long-Acting Risperidone and Oral Antipsychotics in Unstable Schizophrenia [DOI]
  15. 15 Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia [DOI]
  16. 16 An Economic Review of Compliance With Medication Therapy in the Treatment of Schizophrenia [DOI]
  17. 17 Attitudes towards long-acting depot antipsychotics: A survey of patients, relatives and psychiatrists [DOI]
  18. 18 Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR) [DOI]
  19. 19 Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review [DOI]
  20. 20 First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: Systematic review of randomised controlled trials and observational studies [DOI]
  21. 21 Effectiveness of risperidone long-acting injection in first-episode schizophrenia: In naturalistic setting [DOI]
  22. 22 Efficacy and safety of second-generation long-acting injections in schizophrenia [DOI]
  23. 23 Medication noncompliance in schizophrenia: codification and update.
  24. 24 Characteristics and Use Patterns of Patients Taking First-Generation Depot Antipsychotics or Oral Antipsychotics for Schizophrenia [DOI]
  25. 25 Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia [DOI]
  26. 26 Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia [DOI]
  27. 27 Prevention of Relapse in Schizophrenia [DOI]
  28. 28 Family participation in treatment, post-discharge appointment and medication adherence at a Nigerian psychiatric hospital [DOI]
  29. 29 Clinicians’ Attitudes Toward the Use of Long-Acting Injectable Antipsychotics [DOI]
  30. 30 Die Versorgung psychisch Kranker in den Ländern der dritten Welt am Beispiel von Nigeria [DOI]
  31. 31 Experiences of discrimination by people with schizophrenia in Lagos, Nigeria [DOI]
  32. 32 Persistence in Treatment for One Year Among Patients in Nigeria With First-Episode Schizophrenia [DOI]
  33. 33 Discontinuity of Outpatient Antipsychotic Pharmacotherapy: Risperidone Maintenance after Hospitalization [DOI]

Cited by 2

Showing 1 of 2 known citations — external sources report more than can currently be individually listed.

Article metrics

Real usage data collected on this platform.

65

Page views

0

PDF downloads

34

Outbound clicks

2

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.